<DOC>
	<DOCNO>NCT00468715</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth breast cancer cell . Antihormone therapy , bicalutamide , may stop adrenal gland make androgen . PURPOSE : This phase II trial study well bicalutamide work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Bicalutamide Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 6-month efficacy rate bicalutamide first- , second- , third-line therapy patient androgen receptor-positive estrogen receptor- progesterone receptor-negative metastatic breast cancer . Secondary - Determine 6-month progression-free survival patient treated drug . - Evaluate safety drug patient . - Evaluate change estradiol , total free testosterone , sex-hormone bind globulin response androgen blockade patient treat drug . - Evaluate tissue , include cytokeratins 5/6 17 , SPDEF , ALCAM , ERBB2 , FGFR4 , prostate-specific antigen ( PSA ) , use immunohistochemical analysis patient treat drug . OUTLINE : This open-label study . Patients receive oral bicalutamide daily 4 week . Treatment repeat every 4 week 6 month absence disease progression unacceptable toxicity . Patients achieve complete response , partial response , stable disease may continue receive bicalutamide discretion investigator . Patients undergo blood tissue sample collection correlative study . Samples analyze hormonal level , include estradiol , total testosterone , free testosterone , sex-hormone binding globulin , protein , include ALCAM , SPEDF , CK 5/6 , immunohistochemical analysis baseline , course 1 , end study . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 28 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Stage IV disease Measurable nonmeasurable disease Patients HER2/neupositive disease must receive prior trastuzumab ( Herceptin® ) No active brain metastasis leptomeningeal disease History brain metastasis allow provided lesion stable least 3 month document head CT scan MRI brain Hormone receptor status : Estrogen receptor progesterone receptornegative* Androgen receptorpositive* NOTE : *Samples consider positive great 10 % cell nuclei immunoreactive PATIENT CHARACTERISTICS : Male female Menopausal status specify ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN ( unless bone metastasis present absence liver metastasis ) Creatinine ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious medical psychiatric illness No serious active infection No malignancy within past 5 year except nonmelanoma skin cancer No hypersensitivity reaction bicalutamide tablet 's component PRIOR CONCURRENT THERAPY : At least 2 week since prior cytotoxic chemotherapy recover At least 3 week since prior investigational drug At least 4 week since prior major surgery recover Prior neoadjuvant adjuvant chemotherapy allow Any number chemotherapy regimens allow metastatic disease Prior hormonal therapy allow No concurrent chemotherapy , hormonal therapy , immunotherapy , biological therapy No concurrent trastuzumab ( Herceptin® ) No concurrent enrollment another clinical trial investigational procedure perform investigational therapy administer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>